Lisa A Chakrabarti1, Céline Boucherie, Florence Bugault, Marie-Christine Cumont, Caroline Roussillon, Guillaume Breton, Olivier Patey, Geneviève Chêne, Laura Richert, Olivier Lortholary. 1. aUnité de Pathogénie Virale, INSERM U1108, Institut Pasteur, Paris bUniversity Bordeaux, ISPED cINSERM ISPED, Centre INSERM U897-Epidemiologie-Biostatistique, Bordeaux dUnité d'Immunologie Cellulaire, Institut Pasteur eService de Médecine Interne, Hôpital de La Pitié-Salpêtrière, Paris fHôpital Villeneuve St-Georges, Villeneuve St-Georges gCHU de Bordeaux, Pole de santé publique, Service d'information médicale, Bordeaux hUniversité Paris Descartes, Hôpital Necker Enfants malades, APHP, Paris, France.
Abstract
OBJECTIVE: Patients coinfected with HIV and Mycobacterium tuberculosis frequently experience a paradoxical worsening of tuberculosis (TB) symptoms early after the initiation of combination antiretroviral therapy (cART). This immune reconstitution inflammatory syndrome (TB-IRIS) can lead to significant morbidity and needs to be distinguished from TB recurrence due to ineffective treatment. We investigated whether plasma biomarkers could predict the occurrence of TB-IRIS. DESIGN: ANRS 129 BKVIR is a single-arm multicentre trial that enrolled 69 cART-naïve HIV-1-infected patients treated for TB. The patients received once-daily tenofovir/emtricitabine/efavirenz first-line regimen. TB-IRIS cases (IRIS+) were validated by an Event Review Committee. METHODS: A panel of 26 plasma biomarkers was monitored longitudinally for 24 weeks from cART initiation onward, using multiplexed assays and high-sensitivity ELISA. Statistical analyses of biomarkers were adjusted for test multiplicity. RESULTS: One-third of patients (n=23) experienced TB-IRIS. The inflammatory cytokines and chemokines interleukin (IL)-6, IL-8, interferon-gamma-induced protein 10 (IP-10), and tumour necrosis factor-alpha (TNF-α) showed increased plasma levels at week 4 in IRIS-positive (IRIS+) patients (P<0.05 for each biomarker). The soluble IL-2 receptor sCD25, which is released upon CD4 T-cell activation, was significantly increased at week 0 in IRIS+ patients (P<0.05), and remained elevated throughout follow-up. IL-7, a key homeostatic cytokine for CD4 T-cells, showed a trend for higher values in the TB-IRIS group. Both sCD25 and IL-7 baseline levels were independently associated with a shorter time to TB-IRIS occurrence (P=0.005 and P=0.02, respectively). CONCLUSION: These findings support a role for CD4 T-cell activation prior to massive inflammation in the development of TB-IRIS.
OBJECTIVE:Patients coinfected with HIV and Mycobacterium tuberculosis frequently experience a paradoxical worsening of tuberculosis (TB) symptoms early after the initiation of combination antiretroviral therapy (cART). This immune reconstitution inflammatory syndrome (TB-IRIS) can lead to significant morbidity and needs to be distinguished from TB recurrence due to ineffective treatment. We investigated whether plasma biomarkers could predict the occurrence of TB-IRIS. DESIGN: ANRS 129 BKVIR is a single-arm multicentre trial that enrolled 69 cART-naïve HIV-1-infectedpatients treated for TB. The patients received once-daily tenofovir/emtricitabine/efavirenz first-line regimen. TB-IRIS cases (IRIS+) were validated by an Event Review Committee. METHODS: A panel of 26 plasma biomarkers was monitored longitudinally for 24 weeks from cART initiation onward, using multiplexed assays and high-sensitivity ELISA. Statistical analyses of biomarkers were adjusted for test multiplicity. RESULTS: One-third of patients (n=23) experienced TB-IRIS. The inflammatory cytokines and chemokines interleukin (IL)-6, IL-8, interferon-gamma-induced protein 10 (IP-10), and tumour necrosis factor-alpha (TNF-α) showed increased plasma levels at week 4 in IRIS-positive (IRIS+) patients (P<0.05 for each biomarker). The soluble IL-2 receptor sCD25, which is released upon CD4 T-cell activation, was significantly increased at week 0 in IRIS+ patients (P<0.05), and remained elevated throughout follow-up. IL-7, a key homeostatic cytokine for CD4 T-cells, showed a trend for higher values in the TB-IRIS group. Both sCD25 and IL-7 baseline levels were independently associated with a shorter time to TB-IRIS occurrence (P=0.005 and P=0.02, respectively). CONCLUSION: These findings support a role for CD4 T-cell activation prior to massive inflammation in the development of TB-IRIS.
Authors: Afroditi Boulougoura; Erin Gabriel; Elizabeth Laidlaw; Vikram Khetani; Ken Arakawa; Jeanette Higgins; Adam Rupert; Robert J Gorelick; Keith Lumbard; Alice Pau; April Poole; Angela Kibiy; Princy Kumar; Irini Sereti Journal: Open Forum Infect Dis Date: 2019-06-03 Impact factor: 3.835
Authors: Ngomu Akeem Akilimali; Christina C Chang; Daniel M Muema; Tarylee Reddy; Mahomed-Yunus S Moosa; Sharon R Lewin; Martyn A French; Thumbi Ndung'u Journal: Clin Infect Dis Date: 2017-10-16 Impact factor: 9.079
Authors: Colin Stewart Brown; Colette Joanne Smith; Ronan Angus MacCormick Breen; Lawrence Peter Ormerod; Rahul Mittal; Marie Fisk; Heather June Milburn; Nicholas Martin Price; Graham Henry Bothamley; Marc Caeroos Isaac Lipman Journal: BMC Infect Dis Date: 2016-09-06 Impact factor: 3.090
Authors: Christina Gavegnano; Jessica H Brehm; Franck P Dupuy; Aarthi Talla; Susan Pereira Ribeiro; Deanna A Kulpa; Cheryl Cameron; Stephanie Santos; Selwyn J Hurwitz; Vincent C Marconi; Jean-Pierre Routy; Laurent Sabbagh; Raymond F Schinazi; Rafick Pierre Sékaly Journal: PLoS Pathog Date: 2017-12-21 Impact factor: 6.823